Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tempus

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
From Tempus
Via Business Wire
Tickers TEM
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
From Tempus
Via Business Wire
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
From Tempus
Via Business Wire
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
From Tempus
Via Business Wire
Tempus Announces the Clinical Launch of its MRD Testing Portfolio
From Tempus
Via Business Wire
Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next
From Tempus
Via Business Wire
Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types
From Tempus
Via Business Wire
Tempus Introduces Workspaces into its Lens Data Analytics Platform
From Tempus
Via Business Wire
Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024
From Tempus
Via Business Wire
Tempus Contributes De-Identified Cancer Data to Planned Data Enclave
From Tempus
Via Business Wire
Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna
From Tempus
Via Business Wire
Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research
From Tempus
Via Business Wire
Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests
From Tempus
Via Business Wire
Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only
From Tempus
Via Business Wire
Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies
From Tempus
Via Business Wire
Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
From Tempus
Via Business Wire
Tempus Announces New ctDNA Assay, xF Monitor
From Tempus
Via Business Wire
FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test
From Tempus
Via Business Wire
Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
From Tempus
Via Business Wire
Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
From Tempus
Via Business Wire
Tempus Announces Broad Launch of Tempus One
From Tempus
Via Business Wire
Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor
From Tempus
Via Business Wire
Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
From Tempus
Via Business Wire
Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development
From Tempus
Via Business Wire
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
From Tempus
Via Business Wire
Tickers AZN
Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests
From Tempus
Via Business Wire
Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research
From Tempus
Via Business Wire
Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
From Tempus
Via Business Wire
Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022
From Tempus
Via Business Wire
Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
From Tempus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.